Neurocrine Biosciences | NBIX - Actif À Court Terme





Actif À Court Terme Changement Date
AbbVie USD 33.53B 4.47B 2026-03
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Agios Pharmaceuticals USD 834.84M 107.21M 2026-03
ALKERMES USD 1.36B 570.52M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amgen USD 31.48B 2.42B 2026-03
Biogen USD 9.19B 216.3M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
Cytokinetics USD 839.46M 77.51M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Exelixis USD 1.21B 234.65M 2026-03
Gilead Sciences USD 18.64B 1.25B 2026-03
Halozyme Therapeutics USD 1B 177.83M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Nektar Therapeutics USD 266.27M 15.09M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Pfizer USD 42.82B 76M 2026-03
Prothena USD 339.2M 24.01M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Repligen USD 1.16B 23.98M 2026-03
Rigel Pharmaceuticals USD 214.93M 39.53M 2025-09
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Teva Pharmaceutical Industries USD 13.71B 236M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03
Xoma USD 110.71M 5.78M 2025-09